trending Market Intelligence /marketintelligence/en/news-insights/trending/927cot9kxkaayoyh5q9qrg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

US FDA approves Shire's hemophilia A treatment in pediatrics

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


US FDA approves Shire's hemophilia A treatment in pediatrics

The U.S. FDA approved Shire PLC's Adynovate for the treatment of hemophilia A in pediatric patients under 12 years of age.

The drug was first approved for adults with the genetic blood disorder in November 2015.

The regulator also approved the use of the drug in adult and pediatric patients undergoing surgery.